| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
264,900,000 |
| Market
Cap: |
8.27(B) |
| Last
Volume: |
49,305,461 |
Avg
Vol: |
5,854,790 |
| 52
Week Range: |
$4.32 - $31.23 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 606 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
39,348 |
1,060,446 |
4,785,085 |
4,785,085 |
| Total Sell Value |
$1,152,494 |
$23,992,060 |
$86,338,289 |
$86,338,289 |
| Total People Sold |
4 |
5 |
5 |
5 |
| Total Sell Transactions |
4 |
17 |
26 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Junius Daniel M |
Director |
– • – |
2018-03-16 |
4 |
OE |
$4.29 |
$107,250 |
D/D |
25,000 |
209,987 |
|
- |
|
| Johnston David Brannon |
Chief Financial Officer |
• – – |
2018-03-15 |
4 |
AS |
$11.53 |
$115,300 |
D/D |
(10,000) |
180,690 |
|
- |
|
| Johnston David Brannon |
Chief Financial Officer |
• – – |
2018-03-15 |
4 |
OE |
$3.05 |
$30,500 |
D/D |
10,000 |
190,690 |
|
- |
|
| Ryll Thomas |
VP, Technical Operations |
• – – |
2018-02-22 |
4 |
AS |
$5.60 |
$64,372 |
D/D |
(11,495) |
87,184 |
|
- |
|
| Gregory Richard J. |
Executive VP & CSO |
• – – |
2018-02-22 |
4 |
AS |
$5.60 |
$205,201 |
D/D |
(36,643) |
199,413 |
|
- |
|
| Enyedy Mark J |
Chief Executive Officer |
• • – |
2018-02-22 |
4 |
AS |
$5.60 |
$285,992 |
D/D |
(51,070) |
483,768 |
|
- |
|
| Barrows Craig |
Executive VP, General Counsel |
• – – |
2018-02-22 |
4 |
AS |
$5.60 |
$83,272 |
D/D |
(14,870) |
156,537 |
|
- |
|
| Berkenblit Anna |
VP & Chief Medical Officer |
• – – |
2018-02-22 |
4 |
AS |
$5.60 |
$92,747 |
D/D |
(16,562) |
118,662 |
|
- |
|
| Wingrove Theresa |
VP of Regulatory Affairs |
• – – |
2018-02-22 |
4 |
AS |
$5.60 |
$61,779 |
D/D |
(11,032) |
81,883 |
|
- |
|
| Johnston David Brannon |
Chief Financial Officer |
• – – |
2018-02-21 |
4 |
AS |
$10.87 |
$228,922 |
D/D |
(21,060) |
180,690 |
|
- |
|
| Gregory Richard J. |
Executive VP & CSO |
• – – |
2018-02-21 |
4 |
AS |
$10.88 |
$375,208 |
D/D |
(34,486) |
239,094 |
|
- |
|
| Ryll Thomas |
VP, Technical Operations |
• – – |
2018-02-21 |
4 |
AS |
$10.88 |
$129,211 |
D/D |
(11,876) |
96,224 |
|
- |
|
| Berkenblit Anna |
VP & Chief Medical Officer |
• – – |
2018-02-21 |
4 |
AS |
$10.88 |
$188,540 |
D/D |
(17,329) |
144,471 |
|
- |
|
| Barrows Craig |
Executive VP, General Counsel |
• – – |
2018-02-21 |
4 |
AS |
$10.88 |
$168,618 |
D/D |
(15,498) |
168,952 |
|
- |
|
| Enyedy Mark J |
Chief Executive Officer |
• • – |
2018-02-21 |
4 |
AS |
$10.87 |
$736,084 |
D/D |
(67,717) |
532,383 |
|
- |
|
| Wingrove Theresa |
VP of Regulatory Affairs |
• – – |
2018-02-21 |
4 |
AS |
$10.88 |
$123,804 |
D/D |
(11,379) |
90,671 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2018-02-21 |
4 |
S |
$12.00 |
$140,556 |
D/D |
(11,713) |
184,987 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2018-02-20 |
4 |
S |
$11.68 |
$292,000 |
D/D |
(25,000) |
196,700 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2018-02-13 |
4 |
OE |
$4.29 |
$107,250 |
D/D |
25,000 |
221,700 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2018-02-13 |
4 |
S |
$10.01 |
$467,253 |
D/D |
(46,667) |
196,700 |
|
- |
|
| Junius Daniel M |
Director |
– • – |
2018-02-13 |
4 |
OE |
$3.30 |
$154,001 |
D/D |
46,667 |
243,367 |
|
- |
|
| Gregory Richard J. |
Executive VP & CSO |
• – – |
2018-01-08 |
4/A |
AS |
$6.64 |
$19,287 |
D/D |
(2,904) |
273,577 |
|
- |
|
| Barrows Craig |
Executive VP, General Counsel |
• – – |
2017-09-15 |
4/A |
S |
$6.73 |
$151,053 |
D/D |
(22,450) |
184,450 |
|
- |
|
| Barrows Craig |
Executive VP, General Counsel |
• – – |
2017-09-15 |
4/A |
OE |
$4.50 |
$135,000 |
D/D |
30,000 |
206,900 |
|
- |
|
| Barrows Craig |
Executive VP, General Counsel |
• – – |
2017-09-15 |
4 |
S |
$6.73 |
$151,053 |
D/D |
(22,450) |
44,050 |
|
- |
|
257 Records found
|
|
Page 7 of 11 |
|
|
